NCT05610215

Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy

Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: China National Center for Cardiovascular Diseases · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.

Detailed description

After informed consent, 66 eligible admissions will be recruited in 2 centers. Eligible participants will be randomly divided (1:1) into either hybrid or catheter ablation arms, looking for a primary outcome of 1-year freedom from atrial arrhythmias.

Conditions

• Atrial Fibrillation
• Cardiomyopathy, Hypertrophic
• Radiofrequency Ablation

Interventions

Type	Name	Description
PROCEDURE	hybrid ablation	simultaneous thoracoscopic epicardial and catheter endocardial ablation
PROCEDURE	catheter ablation	catheter endocardial ablation

Timeline

• Start date: 2023-02-11
• Primary completion: 2025-12-01
• Completion: 2026-12-01
• First posted: 2022-11-09
• Last updated: 2024-08-30

Locations

1 site across 1 country: China